Gaffin David Joseph

SEC source: 0001127602-24-007146 · form4.xml · nonDerivative · entry 2

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,782

SEC source: 0001127602-24-007146 · form4.xml · nonDerivative · entry 1

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,196

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-24-006558 · form4.xml · derivative · entry 3

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,432

Underlying: Ordinary Shares · 7,431 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-24-006558 · form4.xml · nonDerivative · entry 2

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,507

SEC source: 0001127602-24-006558 · form4.xml · nonDerivative · entry 1

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,807

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-24-006169 · form4.xml · derivative · entry 6

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 7,177 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-24-006169 · form4.xml · nonDerivative · entry 4

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,376

SEC source: 0001127602-24-006169 · form4.xml · nonDerivative · entry 3

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,370

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-24-006169 · form4.xml · derivative · entry 5

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,709

Underlying: Ordinary Shares · 6,355 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-24-006169 · form4.xml · nonDerivative · entry 2

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,193

SEC source: 0001127602-24-006169 · form4.xml · nonDerivative · entry 1

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,062

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-24-004629 · form4.xml · nonDerivative · entry 2

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,707

SEC source: 0001127602-24-004629 · form4.xml · nonDerivative · entry 1

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,190

F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 18

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,757

Underlying: Ordinary Shares · 603 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F14 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F14 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 17

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,027

Underlying: Ordinary Shares · 2,412 shares

Expires 2033-02-23

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F13 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 16

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,043

Underlying: Ordinary Shares · 118 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F12 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 8/3/2023.

F12 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 8/3/2023.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 15

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,388

Underlying: Ordinary Shares · 576 shares

Expires 2032-08-03

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F11 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 8/3/2023.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 14

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,064

Underlying: Ordinary Shares · 373 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F10 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F10 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 13

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,674

Underlying: Ordinary Shares · 1,992 shares

Expires 2032-02-18

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F9 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 12

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,863

Underlying: Ordinary Shares · 291 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F8 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F8 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 11

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,303

Underlying: Ordinary Shares · 2,378 shares

Expires 2031-02-22

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F7 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 10

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,177

Underlying: Ordinary Shares · 140 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 9

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,040

Underlying: Ordinary Shares · 2,352 shares

Expires 2030-02-20

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 8

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,833

Underlying: Ordinary Shares · 2,133 shares

Expires 2029-02-21

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 7

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,589

Underlying: Ordinary Shares · 1,089 shares

Expires 2028-02-16

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 6

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,799

Underlying: Ordinary Shares · 799 shares

Expires 2027-02-17

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 5

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,719

Underlying: Ordinary Shares · 719 shares

Expires 2026-02-28

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 4

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,104

Underlying: Ordinary Shares · 354 shares

Expires 2025-02-26

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 3

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,499

Underlying: Ordinary Shares · 499 shares

Expires 2024-03-03

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-23-022139 · form4.xml · derivative · entry 3

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,925

Underlying: Ordinary Shares · 1,974 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 8/3/2023.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 8/3/2023.

SEC source: 0001127602-23-022139 · form4.xml · nonDerivative · entry 2

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,950

SEC source: 0001127602-23-022139 · form4.xml · nonDerivative · entry 1

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,827

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-23-007178 · form4.xml · derivative · entry 5

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,154

Underlying: Ordinary Shares · 30,154 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-23-007178 · form4.xml · derivative · entry 4

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,615

Underlying: Ordinary Shares · 120,615 shares

Expires 2033-02-23

F3 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-23-007178 · form4.xml · derivative · entry 3

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,572

Underlying: Ordinary Shares · 7,286 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-23-007178 · form4.xml · nonDerivative · entry 2

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,853

SEC source: 0001127602-23-007178 · form4.xml · nonDerivative · entry 1

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,077

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-23-006509 · form4.xml · derivative · entry 11

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 6,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F5 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-23-006509 · form4.xml · nonDerivative · entry 8

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,791

SEC source: 0001127602-23-006509 · form4.xml · nonDerivative · entry 7

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,813

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-23-006509 · form4.xml · derivative · entry 10

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,037

Underlying: Ordinary Shares · 7,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-23-006509 · form4.xml · nonDerivative · entry 6

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,938

SEC source: 0001127602-23-006509 · form4.xml · nonDerivative · entry 5

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,486

F2 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 20, 2020 with a three-year performance period that ended on December 31, 2022 (the "2020 PRSUs"). The vesting of this portion of the 2020 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2020 PRSUs.

SEC source: 0001127602-23-006509 · form4.xml · nonDerivative · entry 4

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,018

SEC source: 0001127602-23-006509 · form4.xml · nonDerivative · entry 3

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,087

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-23-006509 · form4.xml · derivative · entry 9

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,691

Underlying: Ordinary Shares · 6,230 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-23-006509 · form4.xml · nonDerivative · entry 2

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,051

SEC source: 0001127602-23-006509 · form4.xml · nonDerivative · entry 1

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,996

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-22-020611 · form4.xml · derivative · entry 2

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,899

Underlying: Ordinary Shares · 7,899 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · kind: This award was granted in connection with the Reporting Person's promotion.

F4 · derivative.exercise_date: Shares underlying the restricted stock unit award vest in four equal annual installments commencing on 8/3/2023.

F4 · derivative.expiration_date: Shares underlying the restricted stock unit award vest in four equal annual installments commencing on 8/3/2023.

SEC source: 0001127602-22-020611 · form4.xml · derivative · entry 1

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,812

Underlying: Ordinary Shares · 28,812 shares

Expires 2032-08-03

F1 · kind: This award was granted in connection with the Reporting Person's promotion.

F2 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 8/3/2023.